Changes in intrinsic subtype of breast cancer during tumor progression in the same patient

Chungyeul Kim, Jungjoo Lee, Wonyoung Lee, Aeree Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) and Ki67 are important prognostic factors and key variables in classification of the intrinsic subtype, which is essential for choice of adjuvant therapy in breast cancer management. There has been earlier reports that instability of hormonal and HER2 status during progression of tumor. However, breast cancer treatment guidelines recently recommended using the intrinsic subtype that is determined by four immunohistochemical (IHC) assays, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. The purpose of study was to investigate whether the intrinsic subtype changes during the tumor progression from ductal carcinoma in situ (DCIS) to lymph node metastasis. The study included 90 patients with breast cancer in Korea University Guro Hospital, between 1992 and 2008. All individuals had DCIS, invasive carcinoma and lymph node metastasis lesion. IHC staining for ER, PR, HER2 and Ki67 as well as SISH assay for HER2 gene amplification was done with following standard method. Overall 25% of breast cancer changed their intrinsic phenotype during progression. Study demonstrated that a subset of breast cancers can change their intrinsic subtype during cancer progression. These changes have an impact on patient prognosis and management, because each breast cancer subtype has their own differently optimized treatment options according to St. Gallen and NCCN guideline.

Original languageEnglish
Pages (from-to)15184-15190
Number of pages7
JournalInternational Journal of Clinical and Experimental Pathology
Volume8
Issue number11
Publication statusPublished - 2015

Fingerprint

Breast Neoplasms
Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Progesterone Receptors
Estrogen Receptors
Lymph Nodes
Guidelines
Neoplasm Metastasis
erbB-1 Genes
Gene Amplification
Korea
Therapeutics
human ERBB2 protein
Hormones
Staining and Labeling
Carcinoma
Phenotype

Keywords

  • Breast cancer
  • Intrinsic subtype
  • Tumor progression

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Changes in intrinsic subtype of breast cancer during tumor progression in the same patient. / Kim, Chungyeul; Lee, Jungjoo; Lee, Wonyoung; Kim, Aeree.

In: International Journal of Clinical and Experimental Pathology, Vol. 8, No. 11, 2015, p. 15184-15190.

Research output: Contribution to journalArticle

@article{838498d192d14278a3375b01819ae7a5,
title = "Changes in intrinsic subtype of breast cancer during tumor progression in the same patient",
abstract = "Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) and Ki67 are important prognostic factors and key variables in classification of the intrinsic subtype, which is essential for choice of adjuvant therapy in breast cancer management. There has been earlier reports that instability of hormonal and HER2 status during progression of tumor. However, breast cancer treatment guidelines recently recommended using the intrinsic subtype that is determined by four immunohistochemical (IHC) assays, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. The purpose of study was to investigate whether the intrinsic subtype changes during the tumor progression from ductal carcinoma in situ (DCIS) to lymph node metastasis. The study included 90 patients with breast cancer in Korea University Guro Hospital, between 1992 and 2008. All individuals had DCIS, invasive carcinoma and lymph node metastasis lesion. IHC staining for ER, PR, HER2 and Ki67 as well as SISH assay for HER2 gene amplification was done with following standard method. Overall 25{\%} of breast cancer changed their intrinsic phenotype during progression. Study demonstrated that a subset of breast cancers can change their intrinsic subtype during cancer progression. These changes have an impact on patient prognosis and management, because each breast cancer subtype has their own differently optimized treatment options according to St. Gallen and NCCN guideline.",
keywords = "Breast cancer, Intrinsic subtype, Tumor progression",
author = "Chungyeul Kim and Jungjoo Lee and Wonyoung Lee and Aeree Kim",
year = "2015",
language = "English",
volume = "8",
pages = "15184--15190",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "11",

}

TY - JOUR

T1 - Changes in intrinsic subtype of breast cancer during tumor progression in the same patient

AU - Kim, Chungyeul

AU - Lee, Jungjoo

AU - Lee, Wonyoung

AU - Kim, Aeree

PY - 2015

Y1 - 2015

N2 - Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) and Ki67 are important prognostic factors and key variables in classification of the intrinsic subtype, which is essential for choice of adjuvant therapy in breast cancer management. There has been earlier reports that instability of hormonal and HER2 status during progression of tumor. However, breast cancer treatment guidelines recently recommended using the intrinsic subtype that is determined by four immunohistochemical (IHC) assays, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. The purpose of study was to investigate whether the intrinsic subtype changes during the tumor progression from ductal carcinoma in situ (DCIS) to lymph node metastasis. The study included 90 patients with breast cancer in Korea University Guro Hospital, between 1992 and 2008. All individuals had DCIS, invasive carcinoma and lymph node metastasis lesion. IHC staining for ER, PR, HER2 and Ki67 as well as SISH assay for HER2 gene amplification was done with following standard method. Overall 25% of breast cancer changed their intrinsic phenotype during progression. Study demonstrated that a subset of breast cancers can change their intrinsic subtype during cancer progression. These changes have an impact on patient prognosis and management, because each breast cancer subtype has their own differently optimized treatment options according to St. Gallen and NCCN guideline.

AB - Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) and Ki67 are important prognostic factors and key variables in classification of the intrinsic subtype, which is essential for choice of adjuvant therapy in breast cancer management. There has been earlier reports that instability of hormonal and HER2 status during progression of tumor. However, breast cancer treatment guidelines recently recommended using the intrinsic subtype that is determined by four immunohistochemical (IHC) assays, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. The purpose of study was to investigate whether the intrinsic subtype changes during the tumor progression from ductal carcinoma in situ (DCIS) to lymph node metastasis. The study included 90 patients with breast cancer in Korea University Guro Hospital, between 1992 and 2008. All individuals had DCIS, invasive carcinoma and lymph node metastasis lesion. IHC staining for ER, PR, HER2 and Ki67 as well as SISH assay for HER2 gene amplification was done with following standard method. Overall 25% of breast cancer changed their intrinsic phenotype during progression. Study demonstrated that a subset of breast cancers can change their intrinsic subtype during cancer progression. These changes have an impact on patient prognosis and management, because each breast cancer subtype has their own differently optimized treatment options according to St. Gallen and NCCN guideline.

KW - Breast cancer

KW - Intrinsic subtype

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85013422920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013422920&partnerID=8YFLogxK

M3 - Article

C2 - 26823864

AN - SCOPUS:85013422920

VL - 8

SP - 15184

EP - 15190

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 11

ER -